1887

Abstract

Using a CD4-capture immunoassay for gp120, several strains of human immunodeficiency virus type 1 (HIV-1) grown in CD4-expressing T lymphoblastoid cells were found to contain little CD4-reactive gp120 (0.3–1.0 ng/ml) relative to virus titre (10–10 TCID/ml) and p24 antigen (80–1000 ng/ml). The measured CD4-reactive gp120 concentrations of HIV-1 suspensions grown in CD4-negative human neuroblastoma cells were 100- to 10000-fold greater than those of HIV-1 grown in CD4-positive lymphoblastoid cells, even though both virus suspensions contained abundant viral gp120 as shown by immunoblot assay. It was postulated that CD4 derived from host cells might be associated with virions, concealing the binding domains of gp120. CD4 association with HIV-1 virions grown in CD4-positive cells was demonstrated directly by immunoblot assay of sucrose gradient-purified virus suspensions and by specific co-sedimentation of I-labelled OKT4 with virions propagated in CD4-expressing cells. CD4 coating of primary HIV-1 isolates grown in peripheral blood mononuclear cells was also observed. The biological significance of CD4 coating of HIV particles remains to be determined.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-9-2015
1996-09-01
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/9/JV0770092015.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-9-2015&mimeType=html&fmt=ahah

References

  1. Arthur L. O., Bess J. W. J., Sowder R. C. I., Benveniste R. E., Mann D. L., Chermann J.-C., Henderson L. E. 1992; Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935–1938
    [Google Scholar]
  2. Bess J. W., Powell P. J., Issaq H. J., Schumack L. J., Grimes M. K., Henderson L. E., Arthur L. O. 1992; Tightly bound zinc in human immunodeficiency virus type I human T-cell leukemia virus type I, and other retroviruses. Journal of Virology 66:840–847
    [Google Scholar]
  3. Bour S., Geleziunas R., Wainberg M. A. 1995; The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiological Reviews 59:63–93
    [Google Scholar]
  4. Bym R. A., Sekigawa I., Chamow S. M., Johnson J. S., Gregory T. J., Capon D. J., Groopman J. E. 1989; Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. Journal of Virology 63:4370–4375
    [Google Scholar]
  5. Capobianchi M. R., Fais S., Castilletti C., Gentile M., Ameglio F., Dianzani F. 1994; A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. Journal of Infectious Diseases 169:886–889
    [Google Scholar]
  6. Chirmule N., Kalyanaraman V., Oyaizu N., Pahwa S. 1988; Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses. Journal of Acquired Immune Deficiency Syndromes 1:425–430
    [Google Scholar]
  7. Clapham P. R., McKnight A., Weiss R. A. 1992; Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. Journal of Virology 66:3531–3537
    [Google Scholar]
  8. Connor R. I., Ho D. D. 1994; Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. Journal of Virology 68:4400–4408
    [Google Scholar]
  9. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. 1989; Plasma viremia in human immunodeficiency virus infection. New England Journal of Medicine 321:1626–1631
    [Google Scholar]
  10. Crise B., Buonocore L., Rose J. K. 1990; CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. Journal of Virology 64:5585–5593
    [Google Scholar]
  11. Crowe S. M., Mills J. M., Kirihara J., Boothman J., Marshall J. A., McGrath M. S. 1990; Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Research and Human Retroviruses 6:1031–1038
    [Google Scholar]
  12. Crowe S. M., Mills J., Elbeik T., Lifson J. D., Kosek J., Marshall J. A., Engeleman E. G., McGrath M. S. 1992; Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: a possible mechanism of T lymphocyte depletion in vivo. Clinical Immunology and Immunopathology 65:143–151
    [Google Scholar]
  13. Crowe S. M., Vardaxis N. J., Kent S. J., Maerz A. L., Hewish M. J., McGrath M. S., Mills J. 1994; HIV infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans . Journal of Leukocyte Biology 56:318–327
    [Google Scholar]
  14. Ezekowitz R. A. B., Kuhlman M., Groopman J. E., Byrn R. A. 1989; A human serum mannose-binding protein inhibits infection by the human immunodeficiency virus. Journal of Experimental Medicine 169:185–196
    [Google Scholar]
  15. Franke E. K., Yuan H. E. K., Luban J. 1994; Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359–362
    [Google Scholar]
  16. Gelderblom H. R. 1991; Ultrastructural studies on lentiviruses. In Accessory Cells in HIV and Other Retroviral Infections: Morphological and Functional Aspects pp 50–68 Edited by Racz P., Dijkstra C. D., Gluckman J.-C. Basel: Karger;
    [Google Scholar]
  17. Gershoni J. M., Denisova G., Raviv D., Smordinsky N. I., Buyaner D. 1993; HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB Journal 7:1185–1187
    [Google Scholar]
  18. Gilbert M. J., Kirihara J., Mills J. 1991; Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein gp120. Journal of Clinical Microbiology 29:142–147
    [Google Scholar]
  19. Gilbert M. J., Brigido L., Müller W. E. G., Hansen J. E., Ezekowitz R. A., Mills J. 1993; Screening of inhibitors of HIV-gp120-CD4 binding using an enzyme-linked immunosorbent assay. Journal of Virological Methods 42:1–12
    [Google Scholar]
  20. Greenwood F. C., Hunter W. M., Glover J. S. 1963; The preparation of 131I-labelled human growth hormone of high specific activity. Biochemical Journal 89:114
    [Google Scholar]
  21. Henderson L. E., Sowder R., Copeland T. D., Oroszlan S., Arthur L. O., Robey W. G., Fischinger P. J. 1987; Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. Journal of Virology 61:629–632
    [Google Scholar]
  22. Ho D. D., Moudgil T., Alam M. 1989; Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. New England Journal of Medicine 321:1621–1625
    [Google Scholar]
  23. Hoxie J. A., Fitzharris T. P., Youngbar P. R., Matthews D. M., Rackowski J. L., Radka S. F. 1987; Nonrandom association of cellular antigens with HTLV-III virions. Humoral Immunology 18:39–52
    [Google Scholar]
  24. Jabbar M. A., Nayak D. P. 1990; Intracellular interaction of human immunodeficiency vims type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. Journal of Virology 64:6297–6304
    [Google Scholar]
  25. Jackson D. C. 1980; Some effects of chloramine T induced radio-iodination on the physico-chemical properties of oligomeric proteins. Journal of Immunological Methods 34:253–260
    [Google Scholar]
  26. Laemmli U. K. 1970; Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
    [Google Scholar]
  27. Lasky L. A., Nakamura G., Smith D. H., Fennie C., Shimasaki G., Patzer E., Berman P., Gregory T., Capon D. J. 1987; Delineation of a region of the human immunodeficiency vims type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50:975–985
    [Google Scholar]
  28. Layne S. P., Merges M. J., Dembo M., Spouge J. L., Nara P. L. 1990; HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 346:277–279
    [Google Scholar]
  29. Meerloo T., Parmentier H. K., Osterhaus A. D. M. E., Goudsmit J., Schuurman H.-J. 1992; Modulation of cell surface molecules during HIV-1 infection of H9 cells. An immunoelectron microscopic study. AIDS 6:1105–1116
    [Google Scholar]
  30. Miedema F., Petit A. J., Terpstra F. G., Schattenkerk J. K., De-Wolf F., Al B. J., Roos M., Lange J. M., Danner S. M., Goudsmit J., Schellekens P. T. A. 1988; Immunological abnormalities in human immunodeficiency vims (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before the CD4+ T helper cell depletion occurs. Journal of Clinical Investigation 82:1908–1914
    [Google Scholar]
  31. Moore J. P., Wallace L. A., Pollett E. A., McKeating J. A. 1989; Anenzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 3:155–63
    [Google Scholar]
  32. Moore J. P., McKeating J. A., Norton W. A., Sattentau Q. J. 1991; Direct measurement of implications for vims-cell binding and fusion reactions and their neutralization by soluble CD4. Journal of Virology 65:1133–1140
    [Google Scholar]
  33. Moore J. P., McKeating J. A., Huang Y. X., Ashkenazzi A., Ho D. D. 1992; Virions of primary human immunodeficiency vims type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of Virology 66:235–43
    [Google Scholar]
  34. Oh S. K., Cruikshank W. W., Raina J., Blanchard G. C., Adler W. H., Walker J., Kornfeld H. 1992; Identification of HIV-1 envelope glycoprotein in the semm of AIDS and ARC patients. Journal of Immunology 5:251–256
    [Google Scholar]
  35. Ou C. Y., Kwok S., Mitchell S. W., Mack D. H., Sninsky J. J., Krebs J. W., Feorino P., Warfield D., Schochetman G. 1988; DNA amplification for direct amplification of HIV in DNA of peripheral blood mononuclear cells. Science 239:295–297
    [Google Scholar]
  36. Peakman M., Senaldi G., Foote N., McManus T. J., Vergani D. 1992; Naturally occurring soluble CD4 in patients with human immunodeficiency vims infection. Journal of Infectious Diseases 165:799–804
    [Google Scholar]
  37. Popovic M., Sarngadharen M. G., Read E., Gallo R. C. 1984; Detection, isolation and continuous production of cytopathic retrovimses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497–500
    [Google Scholar]
  38. Reddy M. M., Vodian M., Grieco M. H. 1990; Elevated levels of CD4 antigen in sera of human immunodeficiency vims-infected populations. Journal of Clinical Microbiology 28:1744–1746
    [Google Scholar]
  39. Reed L. J., Muench H. 1938; A simple method for estimating fifty percent endpoints. American Journal of Hygiene 27:493–497
    [Google Scholar]
  40. Schnittman S. M., Greenhouse J. J., Psallidopoulos M. C., Baseler M., Salzman N. P., Fauci A. S., Lane H. G. 1990; Increasing viral burden in CD4+ T cells from patients with human immunodeficiency vims (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Annals of Internal Medicine 113:438–443
    [Google Scholar]
  41. Schols D., Pauwels R., Desmyter J., De Clercq E. 1992; Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency vims demonstrated by FACS analysis. Virology 189:374–376
    [Google Scholar]
  42. Simpson A. J. G., Singer D., McCuthchan T. F., Sacks D. L., Sher A. 1983; Evidence that schistosome MHC antigens are not synthesized by the parasite but are acquired from the host as intact glycoproteins. Journal of Immunology 131:962–965
    [Google Scholar]
  43. Sodroski J., Goh W. C., Rosen G., Campbell K., Haseltine W. A. 1986; Role of HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322:470–474
    [Google Scholar]
  44. Spear G. T. 1993; Interaction of non-antibody factors with HIV in plasma. AIDS 7:1149–1157
    [Google Scholar]
  45. Sweet R. W., Truneh A., Hendrickson W. A. 1991; CD4: its stmcture, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Current Opinions in Biotechnology 2:622–633
    [Google Scholar]
  46. Tateno M., Gonzalez-Scarano F., Levy J. A. 1989; Human immunodeficiency vims can infect CD4-negative human fibroblastoid cells. Proceedings of the National Academy of Sciences, USA 86:4287–4290
    [Google Scholar]
  47. Tateno M., Levy J. A. 1988; MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency vims (HIV). Virology 167:299–301
    [Google Scholar]
  48. Thali M., Bukovsky A., Kondo E., Rosenwirth B., Walsh C. T., Sodroski J., Gottlinger H. G. 1994; Functional association of cyclophilin A with HIV-1 virions. Nature 372:363–365
    [Google Scholar]
  49. Weiss R. A., Clapham P. R., McClure M. O., McKeating J. A., McKnight A., Dalgleish A. G., Sattentau Q. J., Weber J. N. 1988; Human immunodeficiency viruses: neutralization and receptors. Journal of Acquired Immune Deficiency Syndromes 1:536–541
    [Google Scholar]
  50. Werner A., Winskowsky G., Kurth R. 1990; Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. Journal of Virology 64:6252–6256
    [Google Scholar]
  51. Wilkinson P. C. 1980; Leukocyte locomotion and chemotaxis: effects of bacteria and viruses. Reviews of Infectious Diseases 2:293–318
    [Google Scholar]
  52. Willey R. L., Bonafacino J. S., Potts B. J., Martin M. A., Klausner R. D. 1988; Biosynthesis, cleavage, and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gp160. Proceedings of the National Academy of Sciences, USA 85:9580–9584
    [Google Scholar]
  53. Willey R. L., Maldarelli F., Martin M. A., Strebel K. 1992a; Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. Journal of Virology 66:226–234
    [Google Scholar]
  54. Willey R. L., Maldarelli F., Martin M. A., Strebel K. 1992b; Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. Journal of Virology 66:7193–7200
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-9-2015
Loading
/content/journal/jgv/10.1099/0022-1317-77-9-2015
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error